Azopt

Quick links to important sections

Azopt

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azopt

Quick Facts

Property Description
Active ingredient Brinzolamide
Form Ophthalmic Suspension (Eye Drops)
Pharmacological class Carbonic Anhydrase Inhibitor (CAI)
General purpose Lowering Intraocular Pressure (IOP)
Origin Synthetic Compound

Azopt: Definition and Pharmaceutical Classification

Azopt is a highly specific prescription-only medication intended for the treatment of elevated pressure inside the eye, delivered via topical ocular administration. Its active chemical substance is Brinzolamide, which is classified by the World Health Organization as a Carbonic Anhydrase Inhibitor (CAI), positioning it as a key tool in ocular pressure management. Brinzolamide is a synthetic compound that falls under the category of a sulfonamide derivative, a classification that informs its biochemical structure and targeted action. Its single-ingredient formulation allows for a focused therapeutic approach to pressure control.

The Unique Form of Brinzolamide Ophthalmic Suspension

The physical form of the medicine is an ophthalmic suspension, which distinguishes it from traditional clear eye solutions. This specialized delivery system contains fine, undissolved particles of Brinzolamide dispersed in an aqueous base, necessitating gentle shaking prior to application to ensure consistent dosing. This specialized suspension formula is designed to optimize the contact time of the active ingredient with the ocular surface for effective pressure management.

General Purpose of This Ocular Hypotensive Drug

the core function of Azopt is to act as an ocular hypotensive drug, meaning its primary goal is the effective lowering of intraocular pressure (IOP). It functions as a targeted Pressure Regulator by influencing the enzymatic process that generates aqueous humor—the fluid produced inside the eye. This essential pressure reduction is utilized in clinical practice to relieve chronic mechanical stress within the ocular system.

Regulatory References

  1. Carbonic Anhydrase Inhibitor (CAI)
  2. WHO ATC Code S01EC04
  3. sulfonamide derivative
  4. lowering of intraocular pressure (IOP)

What side effects are possible with Azopt?

Possible side effects and safety information

Regulatory documents organize the safety profile of Azopt (brinzolamide) by the frequency of reported adverse reactions and the body systems affected. As a sulfonamide derivative, brinzolamide is absorbed systemically even after topical application, which informs the potential for both local and systemic effects, including those characteristic of the sulfonamide class.


Official Adverse Reaction Classifications

Adverse reactions are classified by incidence as observed in clinical studies:

  • Common Reactions (Affecting 1% to 10% of Patients): The most frequent effects relate to the eye and sensory systems. These include blurred vision, ocular discomfort, foreign body sensation, and ocular hyperemia (redness). Systemically, the most common effect is dysgeusia (a bitter or unusual taste perception), along with headache and rhinitis.
  • Uncommon Reactions (Affecting 0.1% to 1% of Patients): Less frequent effects include dry mouth, dizziness, diarrhea, nausea, and alopecia (hair loss).

Serious Systemic Safety Considerations

Due to systemic absorption, the possibility exists for rare, but severe, reactions associated with the sulfonamide class, such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and serious blood dyscrasias (disorders of blood components). This systemic potential is a mandatory note in official regulatory labeling.

Population-Specific Safety Notes

The medicine is contraindicated in individuals with severe renal impairment (creatinine clearance less than 30 mL/min) because brinzolamide is primarily eliminated by the kidneys. Caution is also noted for patients with compromised corneas or those with hepatic impairment. The safety and effectiveness in pediatric patients under 18 years of age have not been established in clinical studies. Co-administration with oral Carbonic Anhydrase Inhibitors is not recommended due to the potential for additive systemic effects.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Azopt

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Potential for systemic effects, including disturbances in serum electrolytes and the development of metabolic acidosis.
Physiological systems affected Affects the body's acid-base balance and electrolyte balance; possible nervous system effects (e.g., confusion or drowsiness).
Dose-related or exposure-related factors Risk is noted following accidental oral overdose or acute systemic toxicity.
Emergency-response statements Contact a Poison Control Center and seek immediate medical attention.
When immediate medical help is required Urgent professional medical care is required following accidental oral administration of an overdose.

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification Consequences listed include severe disturbances of the acid-base balance and major electrolyte imbalance.
Overdose-context constraints Management addresses the consequences of systemic carbonic anhydrase inhibition.

Resulting Overdose Structure

Official overdose statements:

  • No specific antidote is known for Brinzolamide overdose.
  • Management should consist of symptomatic and supportive treatment.
  • Continuous clinical and laboratory monitoring is required, specifically of serum electrolyte levels (potassium) and blood pH levels.

Connection to the overall overdose profile (2–4 sentences): The regulatory profile establishes that acute systemic exposure may result in serious consequences typical of excessive carbonic anhydrase inhibition. Official guidance mandates immediate medical attention and confirms that treatment is limited to supportive care focused on stabilizing the patient’s fluid and electrolyte status, as no specific antidote is available.

Therapeutic Uses of Azopt

Azopt's Therapeutic Uses: Addressing Elevated Eye Pressure

Azopt (brinzolamide) is used in situations involving certain distressing symptoms related to organ-specific functional stress in the eye. It is relevant for easing symptoms associated with acute or episodic changes in eye pressure, which is a key factor in conditions where functional stability becomes affected. This type of supportive care is applied across domains where additional symptomatic support is needed.

Azopt is commonly used to help with managing elevated eye pressure in adult patients. This applies to conditions presenting with systemic or localized discomfort, specifically ocular hypertension and open-angle glaucoma.

It is commonly used when short-term symptomatic assistance is needed to manage eye pressure. May be part of symptomatic management when used alone or alongside other agents. This assists with maintaining functional stability and provides support that helps ease the overall symptom burden associated with these conditions.


Quick Fact: Relevant for Easing Discomfort


Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Azopt?

Eligibility for Azopt (brinzolamide) is strictly governed by regulatory labeling, defining who is approved for use and who must not use the medicine.


Populations Contraindicated from Use

Official labeling contraindicates the use of Azopt in patients with a known hypersensitivity to brinzolamide or any component of the formulation. Use is also strictly prohibited for individuals with a history of sulfonamide hypersensitivity (sulfa drug allergy), as brinzolamide is a sulfonamide derivative that undergoes systemic absorption. Furthermore, Azopt is contraindicated in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) and those with hyperchloraemic acidosis.


Age and Organ Function Restrictions

  • Adults: The medicine is approved and indicated for adult patients (ge 18 years of age).
  • Pediatric Use: Safety and efficacy have not been established in pediatric patients (0–17 years of age), making its use not recommended in this population.
  • Renal/Hepatic Impairment: While severe renal impairment is a contraindication, use in patients with hepatic impairment is advised with caution because its safety has not been studied in this specific group.

Pregnancy and Lactation Status

There are no adequate and well-controlled studies in pregnant women. Azopt should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. For lactation, there is no data on its presence in human milk, though it was detected in animal studies, necessitating a cautious evaluation by a health professional.

What should I know about interactions with other medicines?

Azopt (brinzolamide ophthalmic suspension) is a topical carbonic anhydrase inhibitor (CAI) that is absorbed into the body's system, and therefore, its drug interaction profile is related to its systemic activity.

Documented Pharmacologic Interactions

  • Oral Carbonic Anhydrase Inhibitors: The concomitant use of Azopt and oral carbonic anhydrase inhibitors is not recommended. This restriction is based on the potential for an additive effect on the known systemic side effects of CAI drugs, which can include disturbances to the body's acid-base and electrolyte balance.
  • High-Dose Salicylate Therapy: Due to rare instances of acid-base and electrolyte alterations reported in patients treated with oral carbonic anhydrase inhibitors and high-dose salicylates, the potential for such an interaction must be considered when Azopt is co-administered with high-dose salicylate drugs.

Procedural Interaction Rules

  • Other Topical Ophthalmic Products: Azopt can be used concurrently with other topical eye drops intended to lower intraocular pressure. However, to prevent drug washout or dilution, the medicines must be administered at least five to ten minutes apart. Eye ointments should be applied last.

Population-Specific Interaction Constraints

  • Caution is advised when prescribing Azopt to patients with a risk of renal impairment because of the potential for metabolic acidosis, a systemic effect that can be worsened by other CAIs or salicylates. The drug has not been studied and is generally not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Mechanism of Action

Targeted Inhibition of Carbonic Anhydrase Isozyme II

The action of Brinzolamide begins with the highly selective and reversible inhibition of the enzyme Carbonic Anhydrase Isozyme II ( CA-II). This enzyme is concentrated within the eye's ciliary processes, the tissue responsible for fluid generation. By binding to the active site of CA-II, the drug interrupts the fundamental reaction that generates bicarbonate ions ( HCO3^-), which are essential for ocular fluid production.


Suppression of Aqueous Humor Secretion

The reduced generation of bicarbonate ions fundamentally disrupts the active transport of sodium ( Na^+) and water across the ciliary epithelium. This molecular cascade suppresses the primary physiological process of aqueous humor secretion by the ciliary body. The ultimate physiological consequence is a reduction in the volume of new fluid entering the eye, which results in a reduced pressure state.


Physiological Constraint and Specificity

The drug's mechanism requires a near-total degree of CA-II inhibition for the suppression of secretion to occur. Furthermore, CA-II is also essential for corneal fluid transport; its inhibition introduces a physiological constraint by potentially compromising the corneal deturgescence mechanism.

Dosage and Administration Information

Official Administration Guidelines for Azopt (Brinzolamide Ophthalmic Suspension 1%)

Azopt is a prescription eye drop administered via the topical ophthalmic route into the conjunctival sac of the affected eye(s). Strict adherence to the documented procedure is required to ensure proper dosing and prevent contamination.

Dosing and Frequency

Guideline Official Instruction
Recommended Dose One drop in the affected eye(s).
Frequency Three times daily (TID) or twice daily (BID), with an option for three times daily if needed for a better response.
Missed Dose If a dose is missed, continue the regimen with the next scheduled dose. Do not use a double dose.
Pediatric Use Safety and efficacy in patients under 18 years of age have not been established, and use is generally not recommended.

Procedural Requirements

  1. Preparation: The bottle must be shaken well immediately before each use to properly suspend the medicine.
  2. Administration: Tilt the head back and place one drop into the conjunctival sac. To reduce the risk of systemic absorption, nasolacrimal occlusion (closing the eyelid for two minutes) is recommended after instillation.
  3. Contamination Risk: The dropper tip must not touch the eye, surrounding structures, or any other surface to prevent contamination, which may lead to serious ocular infection.
  4. Contact Lenses: Soft contact lenses must be removed prior to application. Wait at least 15 minutes after instillation before reinserting the soft contact lenses.
  5. Concomitant Use: If more than one topical ophthalmic drug is used, the medications must be administered at least 5 to 10 minutes apart, with eye ointments administered last.

Recent Clinical Evidence

Azopt: Recent Clinical Evidence

Mechanism of Action and Clinical Use

Azopt (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor approved for lowering elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. The mechanism involves reducing the formation of aqueous humor in the ciliary body, which in turn lowers the pressure inside the eye. Clinical evidence focuses on its efficacy as both monotherapy and adjunctive therapy.


Efficacy as Monotherapy

Studies evaluating brinzolamide as a standalone treatment generally focus on sustained IOP reduction over a 24-hour period. Research has consistently shown that twice-daily or three-times-daily dosing provides a clinically relevant reduction in baseline IOP. The degree of reduction achieved is comparable to other available topical IOP-lowering agents, establishing it as a standard treatment option. Tolerability is a key consideration, and studies often report low incidence of systemic side effects.


Adjunctive Therapy Trials

Brinzolamide is often studied in combination with prostaglandin analogs (e.g., latanoprost) or beta-blockers (e.g., timolol). When added to these therapies, brinzolamide has been shown to provide an additive IOP-lowering effect. These combination studies support its use for patients whose pressure is not adequately controlled with a single medication. The goal of this research is to achieve target IOP levels while maintaining a tolerable adverse event profile, thereby minimizing the need for surgical intervention.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE): Glaucoma: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Azopt (FAQ)

Q: Is it normal to feel a burning sensation when I first start using Azopt?

A: According to the official product information, side effects reported when the medicine is applied can include a burning or stinging sensation or general ocular discomfort. This reaction is generally common and often described as temporary. It is important that users monitor the severity of any discomfort.

Q: What does the term 'carbonic anhydrase inhibitor' mean for patients?

A: This term refers to the medicine’s classification and how it works. Azopt is a Carbonic Anhydrase Inhibitor that acts by reducing the formation of aqueous humor, which is the fluid inside the eye. This process is intended to lower the pressure within the eye.

Q: Is Azopt an antibiotic or steroid?

A: Official documents classify Azopt as a Carbonic Anhydrase Inhibitor (CAI), meaning it is used to lower eye pressure. It is neither an antibiotic nor a steroid. The medicine is, however, chemically related to the sulfonamide class of drugs.

Q: Why is Azopt sometimes prescribed instead of other eye drops?

A: Research indicates that the medicine's efficacy in lowering eye pressure is comparable to that of other available agents. Clinical studies suggest Azopt may be associated with a potential for a lower rate of ocular discomfort compared to some similar glaucoma medicines, which is a characteristic that may be considered in prescribing decisions.

Q: What is the general difference between Azopt and similar drops like Trusopt?

A: Both medicines belong to the same class, Carbonic Anhydrase Inhibitors, and work similarly to reduce eye pressure. The primary difference noted in clinical studies is that Azopt may be associated with a lower rate of ocular discomfort or stinging compared to dorzolamide (Trusopt).

Q: Does Azopt contain preservatives?

A: Yes, the official formulation of the ophthalmic suspension includes the preservative benzalkonium chloride. This is noted in the medicine's regulatory documents as an excipient (non-active ingredient).

Q: How quickly does Azopt typically start working?

A: Official information states that the medicine may begin to reduce intraocular pressure within one to two hours after the first dose. However, the full pressure-lowering effect is generally noted after several weeks of consistent use.

Q: How long can I expect to use Azopt?

A: Azopt is generally designated as a long-term treatment for chronic conditions like glaucoma and ocular hypertension. Its duration of use is described as long-term, and patient eligibility is based on a professional assessment of needs and response.

Q: Can Azopt cause dry eyes?

A: Yes, official adverse reaction reports list dry eye as an uncommon side effect. This is one of several ocular effects noted in clinical trials.

Q: Are there any long-term side effects associated with using Azopt?

A: Clinical studies generally report adverse effects that are local, transient, and mild to moderate in severity. While the medicine is used long-term, severe systemic side effects characteristic of oral Carbonic Anhydrase Inhibitors have not typically been observed with the topical eye drop formulation.

Q: Does Azopt interact with over-the-counter pain relievers like ibuprofen?

A: The official warnings for this medicine highlight a potential risk of interaction when used with High-Dose Salicylate Therapy. Other non-salicylate over-the-counter pain relievers, such as ibuprofen, are not specifically listed in the interaction section of the regulatory label.

Q: Can Azopt be used if I take oral water pills (diuretics)?

A: Official documents caution that use with oral Carbonic Anhydrase Inhibitors is not recommended due to the potential for additive systemic effects. However, there is no specific warning against other classes of diuretics (water pills).

Q: Is there a risk of interaction between Azopt and heart medications?

A: Official documents do not list interactions with general heart medications. However, rare side effects in the cardiac system have been reported, including irregular heart rate and angina pectoris.

Q: Is Azopt safe for older adults (the elderly)?

A: Official regulatory documents contain a dedicated section on Geriatric Use for patients 65 years and older. Information indicates that effectiveness or safety is generally not different for older adult patients compared to other adults.

Q: Why do some people experience blurred vision after using Azopt?

A: Blurred vision is listed as a common, transient (temporary) visual disturbance that may occur immediately after the drops are instilled. This is typically a brief effect related to the suspension formula.

Q: What makes Azopt different from latanoprost drops?

A: The two medicines belong to different pharmacological classes and mechanisms of action. Azopt is a Carbonic Anhydrase Inhibitor (CAI), while latanoprost is a Prostaglandin Analog. Azopt is indicated for use as both monotherapy and adjunctive therapy with medicines from the prostaglandin analog class.

Q: Is there a generic version of Azopt available?

A: Yes, the active ingredient, brinzolamide, is available in a generic ophthalmic suspension formulation. Information on product availability and formulations is regulated and documented.

Q: Can Azopt cause feelings of tiredness or drowsiness?

A: Official reports indicate that uncommon to rare systemic side effects reported include asthenia (lack of energy), somnolence (drowsiness), and fatigue. These are not among the most common effects.

Q: What official information is available about stopping Azopt?

A: Official prescribing information contains a warning that the medicine should not be stopped without consultation. Discontinuing use may lead to an increase in eye pressure. Official information advises against stopping the medicine without consulting a health professional.

Q: Does Azopt affect blood pressure or heart rate?

A: Rare adverse events reported in official documents include irregular heart rate and angina pectoris. No specific effect on blood pressure is listed in the common or uncommon side effects section.

Q: What should I know about using Azopt if I have respiratory issues?

A: Uncommon non-ocular events reported in official documents include effects on the respiratory system, such as dyspnoea (shortness of breath), bronchitis, and pharyngitis. These are not the most common side effects.

Q: Is it normal for the suspension to look cloudy?

A: Yes. The medicine is officially described as a 'white to off-white suspension' and is therefore not a clear solution like many other eye drops. It must always be shaken well before use to ensure consistent dosing.

Q: What are the official usage guidelines for driving or operating machinery while using Azopt?

A: Official warnings advise patients to wait until their vision clears before driving or operating machinery. This is because the medicine may cause transient blurred vision or other visual disturbances that could affect alertness.

How should Azopt be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines specific conditions for storing and disposing of Azopt (brinzolamide ophthalmic suspension) to ensure the product remains sterile and effective.

Condition Type Requirement
Temperature Range Store at room temperature, typically between 4 C and 30 C (39 F and 86 F).
Protection Keep tightly closed and protect from heat, moisture, direct light, and do not freeze.
Post-Opening Stability The medicine must be discarded four weeks after the container is first opened.
Handling Shake well before use. The dropper tip must not contact the eye or any other surface to prevent contamination.
Child Safety Must be kept out of the sight and reach of children.
Disposal Dispose of unused or expired product and all related waste material in accordance with local regulations.

These guidelines mandate a tightly controlled environment and strict in-use stability limits to maintain the integrity of the suspension.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azopt found in:

A-Z Index: